A personalized molecular pathogenesis of MDS

Gustavo Rivero, Steven D. Gore

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The past few years have witnessed rapid progress in the understanding of disease initiation in MDS. Chromosomal abnormalities are seen in about 50 % of patients, with chromosome 5, 7, 8, 11, and 20 most commonly affected. In those with normal karyotype, evidence of recurrent structural abnormalities is missed even with more sophisticated technology such as single-nucleotide polymorphism array (SNPa). In recent years, molecular alterations have deepened our perception of disease heterogeneity and reinforced the clinical observation that treatment response does not occur in stereotyped patterns. In fact, there is growing and convincing evidence that disease heterogeneity and response to treatment are strongly associated with genotypic and epigenetic abnormalities. Globally, MDS genome is impacted by specific mutations that can be classified as mutations that induce chromatin modification, mutations altering spliceosome machinery, and those affecting oncogenes and tumor suppressor genes. The link between chromosomal abnormalities, mutations, disease phenotype, and patterns of treatment response represents a promising challenge that continues to be unraveled.

Original languageEnglish (US)
Title of host publicationMyelodysplastic Syndromes, Second Edition
PublisherSpringer Berlin Heidelberg
Pages97-109
Number of pages13
ISBN (Electronic)9783642362293
ISBN (Print)9783642362286
DOIs
StatePublished - Jan 1 2013

Fingerprint

Mutation
Chromosome Aberrations
Spliceosomes
Chromosomes, Human, Pair 5
Chromosomes, Human, Pair 7
Tumor Suppressor Genes
Karyotype
Oncogenes
Epigenomics
Chromatin
Single Nucleotide Polymorphism
Therapeutics
Genome
Technology
Phenotype

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rivero, G., & Gore, S. D. (2013). A personalized molecular pathogenesis of MDS. In Myelodysplastic Syndromes, Second Edition (pp. 97-109). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-36229-3_6

A personalized molecular pathogenesis of MDS. / Rivero, Gustavo; Gore, Steven D.

Myelodysplastic Syndromes, Second Edition. Springer Berlin Heidelberg, 2013. p. 97-109.

Research output: Chapter in Book/Report/Conference proceedingChapter

Rivero, G & Gore, SD 2013, A personalized molecular pathogenesis of MDS. in Myelodysplastic Syndromes, Second Edition. Springer Berlin Heidelberg, pp. 97-109. https://doi.org/10.1007/978-3-642-36229-3_6
Rivero G, Gore SD. A personalized molecular pathogenesis of MDS. In Myelodysplastic Syndromes, Second Edition. Springer Berlin Heidelberg. 2013. p. 97-109 https://doi.org/10.1007/978-3-642-36229-3_6
Rivero, Gustavo ; Gore, Steven D. / A personalized molecular pathogenesis of MDS. Myelodysplastic Syndromes, Second Edition. Springer Berlin Heidelberg, 2013. pp. 97-109
@inbook{c71faa157a0a4247b1ec4716d30295b1,
title = "A personalized molecular pathogenesis of MDS",
abstract = "The past few years have witnessed rapid progress in the understanding of disease initiation in MDS. Chromosomal abnormalities are seen in about 50 {\%} of patients, with chromosome 5, 7, 8, 11, and 20 most commonly affected. In those with normal karyotype, evidence of recurrent structural abnormalities is missed even with more sophisticated technology such as single-nucleotide polymorphism array (SNPa). In recent years, molecular alterations have deepened our perception of disease heterogeneity and reinforced the clinical observation that treatment response does not occur in stereotyped patterns. In fact, there is growing and convincing evidence that disease heterogeneity and response to treatment are strongly associated with genotypic and epigenetic abnormalities. Globally, MDS genome is impacted by specific mutations that can be classified as mutations that induce chromatin modification, mutations altering spliceosome machinery, and those affecting oncogenes and tumor suppressor genes. The link between chromosomal abnormalities, mutations, disease phenotype, and patterns of treatment response represents a promising challenge that continues to be unraveled.",
author = "Gustavo Rivero and Gore, {Steven D.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-3-642-36229-3_6",
language = "English (US)",
isbn = "9783642362286",
pages = "97--109",
booktitle = "Myelodysplastic Syndromes, Second Edition",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - A personalized molecular pathogenesis of MDS

AU - Rivero, Gustavo

AU - Gore, Steven D.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The past few years have witnessed rapid progress in the understanding of disease initiation in MDS. Chromosomal abnormalities are seen in about 50 % of patients, with chromosome 5, 7, 8, 11, and 20 most commonly affected. In those with normal karyotype, evidence of recurrent structural abnormalities is missed even with more sophisticated technology such as single-nucleotide polymorphism array (SNPa). In recent years, molecular alterations have deepened our perception of disease heterogeneity and reinforced the clinical observation that treatment response does not occur in stereotyped patterns. In fact, there is growing and convincing evidence that disease heterogeneity and response to treatment are strongly associated with genotypic and epigenetic abnormalities. Globally, MDS genome is impacted by specific mutations that can be classified as mutations that induce chromatin modification, mutations altering spliceosome machinery, and those affecting oncogenes and tumor suppressor genes. The link between chromosomal abnormalities, mutations, disease phenotype, and patterns of treatment response represents a promising challenge that continues to be unraveled.

AB - The past few years have witnessed rapid progress in the understanding of disease initiation in MDS. Chromosomal abnormalities are seen in about 50 % of patients, with chromosome 5, 7, 8, 11, and 20 most commonly affected. In those with normal karyotype, evidence of recurrent structural abnormalities is missed even with more sophisticated technology such as single-nucleotide polymorphism array (SNPa). In recent years, molecular alterations have deepened our perception of disease heterogeneity and reinforced the clinical observation that treatment response does not occur in stereotyped patterns. In fact, there is growing and convincing evidence that disease heterogeneity and response to treatment are strongly associated with genotypic and epigenetic abnormalities. Globally, MDS genome is impacted by specific mutations that can be classified as mutations that induce chromatin modification, mutations altering spliceosome machinery, and those affecting oncogenes and tumor suppressor genes. The link between chromosomal abnormalities, mutations, disease phenotype, and patterns of treatment response represents a promising challenge that continues to be unraveled.

UR - http://www.scopus.com/inward/record.url?scp=85031407147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031407147&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-36229-3_6

DO - 10.1007/978-3-642-36229-3_6

M3 - Chapter

AN - SCOPUS:85031407147

SN - 9783642362286

SP - 97

EP - 109

BT - Myelodysplastic Syndromes, Second Edition

PB - Springer Berlin Heidelberg

ER -